What Last Year’s Speakers Enjoyed:
“Good mixture between pharma/biotech. early technologies and late stage developments and academia - provides a more hollistic update on what is important in dermatologic R&D”
Kim Kjoeller, CEO, Union Therapeutics
“Intimate environment with diverse pharmaceutical professionals. Great for learning about what's new and upcoming in dermatology development.”
Kassim Rahawi, Director, immunology Global Medical, Sanofi
“I really enjoyed the workshop which had many engaging discussions from both presenters and audience.”
Xuqiu Lei, Senior Scientist, Discovery Immunology, Merck
“This is my 6th DDDS meeting and each time I walk away with a greater network and understanding of the advancements in dermatology”
Michael Howell, Founder & CEO, Mountaineer Biosciences
Why Last Year’s Attendees Loved the Summit:
“This conference was an incredible opportunity to connect with key players in the dermatology industry. It was inspiring to meet so many industry leaders and learn about the innovative treatments currently in development. We’re already looking forward to returning next year! ”
BD Manager, Symbio
“Firstly, a great program well put together, with leading academic and pharma participants that made this a cutting edge meeting. I found much of the content very valuable and educational. Additionally, the mix of presentations, panel discussions and fireside chats provided value and insights beyond a more regular research meeting.”
Michael Salmon, Senior Director, Immuology & Inflammation, Schrodinger
“I enjoyed the intimate gathering of derm biotech leaders, and the many opportunities to network and connect”
Serena Mandla, CSO & Co-Founder, Noa Therapeutics
“The smaller size of the conference makes it very focused and it's easy to meet other experts including CROs. The speed networking break was great and really made it easier to meet even more people. The sessions were very well planned with very interesting topics and excellent speakers.”
Nikolaos Biris, Senior Director, Structural and Functional Biology, Astria Therapeutics
“Connections and learnings”
Senior Scientist, Takeda
“Good organization and plenty of time to connect with participants.”
Jingping Ge, Associate Bioanalytical Director, Astria Therapeutics
“Variety of talks, both industry and academic.”
Mahesh Raundhal, Principal Scientist | Immune-disease Lead, Sanofi
“Small meeting with networking opportunities, agenda focused and relevant for drug development”
Sandip Datta, Vice President – Medical, Aditum Bio
“Relatively small size which allowed easier interactions with speakers and great networking sessions”
Emmanuel Vial, CDO, Granular Therapeutics
“Diverse discussion of multiple skin diseases; participation level; collaborative spirit of the meeting”
Patricia Giblin, SVP, Research, Ability Biologics
“The sessions were very interesting. The conference offered a unique perspective beyond what you see at typical healthcare conferences. The size was great. Very intimate.”
Senior Director Global Lead, Head of CNS Medical Affairs & Project Immunology, Kyowa Kirin